Tirzepatide for diabetes vs long-acting insulins demonstrated superior glycemic control and weight loss compared among adults with type 2 diabetes.

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

Once-weekly insulin vs once-weekly tirzepatide demonstrated superior safety profiles but inferior weight loss and glycemic control outcomes.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Eli Lilly’s drug tirzepatide, is sold to type 2 diabetics ... metabolic markers (e.g. reducing HbA1c levels, and improving insulin sensitivity) and causing weight loss (through targeting insulin ...